A model from InvestingPro’s Fair Value suite identified Puma Biotechnology Inc. as significantly undervalued in November 2025, a call that preceded a 95.35% gain over the subsequent nine months.
The model, which incorporates discounted cash flow, comparable company analysis and consensus price targets, estimated the shares were trading 77.59% below intrinsic value at $4.73 on November 10, 2025. By September 3, 2026, the stock had reached $9.69, within 0.5% of its 52-week high of $9.74.
Puma Biotech, a biopharmaceutical company focused on cancer therapies, reported revenue of $212 million at the time of the initial signal. By the second quarter of 2026, revenue had increased to $231 million, with NERLYNX generating sequential growth of 15% in the fourth quarter of 2025. The company also returned to profitability in Q2 2026, exceeding market expectations.
InvestingPro’s methodology combines multiple valuation approaches, including DCF, comparable company analysis and dividend discount models where applicable, alongside analyst consensus ranges. The platform’s ProPicks service was cited as the source of the fair-value assessment.
Shares of Puma Biotech have delivered monthly gains exceeding 10%–17% during periods in late 2025 and mid-2026, reflecting sustained investor interest following the valuation signal.
